Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02757872 · ClinicalTrials.gov registry record · Phase 3
Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives
A Phase 3 study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,232
- Enrollment target
NCT02757872: Completed Phase 3 study, sponsored by Albert Einstein College of Medicine.
NCT02757872 is a Phase 3 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 2,232 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (189% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02757872, a Phase 3 study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,232 participants
- Enrollment target
Study Summary
The VITamin D and OmegA-3 TriaL (VITAL; NCT01169259) is an ongoing randomized clinical trial in 25,875 US men and women investigating whether taking dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor (R) fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. The VITAL Kidney Function in Hypertension ancillary study will evaluate the effects of vitamin D or omega-3 fatty acids on kidney function among participants with baseline hypertension.
Primary Outcome
Serum creatinine and cystatin C measurement pre-randomization and year 4
Interventions
- DIETARY_SUPPLEMENT Vitamin D3
- DIETARY_SUPPLEMENT Vitamin D3 placebo
- DIETARY_SUPPLEMENT Fish oil placebo
- DRUG Omega-3 Fatty acids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,232 participants |
| Start Date | 2016-04 |
| Est. Completion | 2022-03-31 |
| Phase | Phase 3 |
What the finished NCT02757872 record still lists
NCT02757872 is an interventional study that assigns participants to a tested intervention. Its 2,232 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (189% higher).
The record links to 0 conditions, and to 4 interventions - of which Vitamin D3 is the first listed.
NCT02757872 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02757872 about?
NCT02757872 is a clinical study titled "Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives". The VITamin D and OmegA-3 TriaL (VITAL; NCT01169259) is an ongoing randomized clinical trial in 25,875 US men and women investigating whether taking dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor (R) fish oil, 1 gram) reduces the risk of developing cancer, heart disease, ...
What is the current status of trial NCT02757872?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,232 participants. The study started on 2016-04. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT02757872?
The interventions under investigation include: Vitamin D3 (DIETARY_SUPPLEMENT), Vitamin D3 placebo (DIETARY_SUPPLEMENT), Fish oil placebo (DIETARY_SUPPLEMENT), Omega-3 Fatty acids (DRUG).
Who is sponsoring clinical trial NCT02757872?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02757872's enrollment target sits among peer trials
2,232 95th of 2000 higher than 1,906 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06831929 · 2,232 participants · NA
HPV Ends Here: Increasing Uptake of the HPV Vaccine
- NCT06939803 · 2,236 participants · NA
AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial.
- NCT04889872 · 2,250 participants · NA
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
- NCT06805513 · 2,250 participants · Phase 3
Actual Use Trial of Tadalafil 5 mg
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia